title: Methodological issues in studying the effect of the new oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) on absorption of iron.
abstract: Although deferoxamine is currently the drug of choice for iron chelation, there is more and more evidence of its toxicity. As a replacement for deferoxamine, 1,2-dimethyl-3-hydroxypyrid-4-one (L1), a new oral iron chelator, is undergoing clinical studies in thalassemic patients. Iron handling in experimental acute iron intoxication is being studied in a multiphase study. Preliminary results suggest that the L1-iron complex is not absorbed from the gastrointestinal tract. Methodological issues in studying iron chelation in the context of acute iron intoxication are presented.
authors.affiliation: Division of Clinical Pharmacology & Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Bentur
authors.forename: J
authors.initials: J
authors.lastname: Klein
authors.forename: M
authors.initials: M
authors.lastname: Levy
authors.forename: N
authors.initials: N
authors.lastname: Olivieri
authors.forename: M
authors.initials: M
authors.lastname: McGuigan
authors.forename: G
authors.initials: G
authors.lastname: Koren
mesh_terms: D000284:Administration, Oral; D000818:Animals; D015913:Chelation Therapy; D000077543:Deferiprone; D004285:Dogs; D007408:Intestinal Absorption / Q000187:drug effects*; D007501:Iron / Q000008:administration & dosage / Q000097:blood* / Q000378:metabolism; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D011728:Pyridones; D000077543:Deferiprone; D007501:Iron